PET-Uptake in Liver Metastases as Method to Predict Tumor Biological Behavior in Patients Transplanted for Colorectal Liver Metastases Developing Lung Recurrence.

colorectal cancer fluorine 18 fluorodeoxyglucose (18F-FDG) positron emission tomography liver metastases liver transplantation lung metastases overall survival pulmonary resection

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
14 Oct 2022
Historique:
received: 07 09 2022
revised: 11 10 2022
accepted: 11 10 2022
entrez: 27 10 2022
pubmed: 28 10 2022
medline: 28 10 2022
Statut: epublish

Résumé

The objective of the study was to determine the impact of PET uptake on liver metastases on overall survival (OS) after resection of pulmonary metastases in patients who had received liver transplantation (LT) due to unresectable colorectal liver-only metastases. Resection of pulmonary colorectal metastases is controversial. Some hospitals offer this treatment to selected patients, whereas other hospitals do not perform the procedure in colorectal cancer patients who develop pulmonary metastases. All patients included in the LT studies who developed pulmonary metastases as first site of relapse, and had resection of these as first treatment, were included in this report. Metabolic tumor volume (MTV) in liver was derived from the pre-transplant PET examinations. OS from time of resection was calculated by the Kaplan−Meier method. Patients with low MTV (<70 cm3) had significantly longer OS from time of resection of pulmonary metastases compared to patients with high MTV (>70 cm3). Patients with low MTV in the liver had 10-year OS from time of pulmonary resections of 86%. Liver MTV values from pre-transplant PET examinations may predict long OS in colorectal cancer patients with a resection of pulmonary metastases developing after LT. Thus, in selected colorectal cancer patients developing pulmonary metastases resection of these metastases should be the treatment of choice.

Identifiants

pubmed: 36291826
pii: cancers14205042
doi: 10.3390/cancers14205042
pmc: PMC9599638
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Oslo University Hospital
Organisme : South-Eastern Norway Health Authority

Références

Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
J Clin Oncol. 2007 Apr 20;25(12):1539-44
pubmed: 17442997
Eur J Nucl Med Mol Imaging. 2018 Feb;45(2):218-225
pubmed: 29026950
JAMA Surg. 2021 Jun 1;156(6):550-557
pubmed: 33787838
Lancet Oncol. 2015 Oct;16(13):1306-15
pubmed: 26338525
Ann Thorac Surg. 2007 Jul;84(1):324-38
pubmed: 17588454
ISRN Oncol. 2011;2011:763245
pubmed: 22091431
Eur J Cancer. 2017 Jan;70:87-98
pubmed: 27907852
J Clin Oncol. 2008 Aug 1;26(22):3672-80
pubmed: 18669451
BJS Open. 2020 Jun;4(3):467-477
pubmed: 32333527
Eur J Surg Oncol. 2021 Sep;47(9):2377-2383
pubmed: 34049768
J Thorac Oncol. 2008 Nov;3(11):1257-66
pubmed: 18978560
Rev Recent Clin Trials. 2018;13(2):139-149
pubmed: 29595113
Transpl Int. 2021 Nov;34(11):2205-2213
pubmed: 34792825
J Am Coll Surg. 2012 Jul;215(1):31-8; discussion 38-40
pubmed: 22621893
Gastroenterology. 2018 Jan;154(1):128-139
pubmed: 28989060
Br J Surg. 2018 May;105(6):736-742
pubmed: 29532908
Lancet. 2013 Jan 26;381(9863):303-12
pubmed: 23177514
Ann Surg. 2013 May;257(5):800-6
pubmed: 23360920
Surgery. 2012 Jun;151(6):860-70
pubmed: 22316439
Lancet Gastroenterol Hepatol. 2021 Nov;6(11):933-946
pubmed: 34506756
Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21
pubmed: 10493478
J Clin Oncol. 2009 Aug 1;27(22):3677-83
pubmed: 19470929
Nucl Med Commun. 2020 Sep;41(9):916-923
pubmed: 32796480
Ann Surg Oncol. 2011 Apr;18(4):1096-103
pubmed: 21042942
Ann R Coll Surg Engl. 2013 Mar;95(2):140-3
pubmed: 23484998
N Engl J Med. 1996 Mar 14;334(11):693-9
pubmed: 8594428
J Clin Oncol. 2011 May 20;29(15):2011-9
pubmed: 21502544
Colorectal Dis. 2012 Jun;14(6):660-70
pubmed: 21689294
Am J Transplant. 2020 Feb;20(2):530-537
pubmed: 31674105
Transpl Int. 2021 Sep;34(9):1722-1732
pubmed: 34448271
Ann Surg. 2013 May;257(5):807-15
pubmed: 23532105
Cancer. 2018 Feb 15;124(4):667-678
pubmed: 29266226
Ann Surg. 2020 Feb;271(2):212-218
pubmed: 31188200
J Clin Oncol. 2010 Nov 1;28(31):4697-705
pubmed: 20921465
Trials. 2019 Dec 12;20(1):718
pubmed: 31831062
Ann Gastroenterol Surg. 2019 Jan 14;3(1):50-56
pubmed: 30697610
World J Surg. 2021 Nov;45(11):3404-3413
pubmed: 34322717
N Engl J Med. 2015 May 14;372(20):1909-19
pubmed: 25970050

Auteurs

Svein Dueland (S)

Experimental Transplantation and Malignancy Research Group, Division of Surgery, Inflammatory Diseases and Transplantation, Oslo University Hospital, 0424 Oslo, Norway.
Section for Transplantation Surgery, Department of Transplantation Medicine, Oslo University Hospital, 0424 Oslo, Norway.

Tor Magnus Smedman (TM)

Department of Oncology, Oslo University Hospital, 0424 Oslo, Norway.
Institute of Clinical Medicine, University of Oslo, 0424 Oslo, Norway.

Harald Grut (H)

Department of Radiology, Vestre Viken Hospital Trust, 3004 Drammen, Norway.

Trygve Syversveen (T)

Department of Radiology and Nuclear Medicine, Oslo University Hospital, 0424 Oslo, Norway.

Lars Hilmar Jørgensen (LH)

Department of Thoracic Surgery, Oslo University Hospital, 0424 Oslo, Norway.

Pål-Dag Line (PD)

Experimental Transplantation and Malignancy Research Group, Division of Surgery, Inflammatory Diseases and Transplantation, Oslo University Hospital, 0424 Oslo, Norway.
Section for Transplantation Surgery, Department of Transplantation Medicine, Oslo University Hospital, 0424 Oslo, Norway.
Institute of Clinical Medicine, University of Oslo, 0424 Oslo, Norway.

Classifications MeSH